Details

Autor(en) / Beteiligte

• Papazian, Laurent
• Forel, Jean-Marie
• Gacouin, Arnaud
• Penot-Ragon, Christine
• Perrin, Gilles
• Loundou, Anderson
• Jaber, Samir
• Arnal, Jean-Michel
• Perez, Didier
• Seghboyan, Jean-Marie
• Constantin, Jean-Michel
• Courant, Pierre
• Lefrant, Jean-Yves
• Guérin, Claude
• Prat, Gwenaël
• Morange, Sophie
• Roch, Antoine

Titel

Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome

Ist Teil von

• The New England journal of medicine, 2010-09, Vol.363 (12), p.1107-1116

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2010

Quelle

MEDLINE

Beschreibungen/Notizen

• The investigators induced muscle paralysis in patients with the acute respiratory distress syndrome (ARDS) by administering a neuromuscular blocking agent, cisatracurium besylate. As compared with placebo, cisatracurium resulted in a lower adjusted 90-day mortality without more severe sequelae of neuromuscular blockade. The acute respiratory distress syndrome (ARDS) is characterized by hypoxemic respiratory failure; it affects both medical and surgical patients. 1 Despite rigorous physiological management, 2 in most studies, ARDS has been fatal in 40 to 60% of patients. 3 – 7 Neuromuscular blocking agents are used in a large but highly variable proportion of patients with ARDS. 8 – 12 Current guidelines indicate that neuromuscular blocking agents are appropriate for facilitating mechanical ventilation when sedation alone is inadequate, most notably in patients with severe gas-exchange impairments. 10 In a four-center randomized, controlled trial of gas exchange in 56 patients with ARDS, 13 infusion of a neuromuscular blocking agent . . .